Myojin et al. [29] recently reported that the PFS and OS of the IL-6-high group were significantly shorter than those of the IL-6-low group of patients with advanced HCC treated with atezolizumab plus bevacizumab. This evidence concerns the gene IL6 and hepatocellular carcinoma.